Background: Minor adverse reactions following transfusion of blood components to cancer patients are not uncommon. Reporting these minor reactions to the transfusion service needs a careful evaluation ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Ruxolitinib demonstrated an improvement in transfused red blood cell volume during a 24-week ...
An ongoing, phase 3, open-label study demonstrated the efficacy of exagamglogene autotemcel (exa-cel) infusion to promote transfusion dependence in patients with transfusion-dependent β-thalassemia ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
New technologies boost safety for patients with cancer who need donated blood. In the seven years since Jeremy Sheldon received a chronic lymphocytic leukemia diagnosis, he has had his fair share of ...
TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and significant health care resource utilization. TDT ...
Anemia and transfusion of red blood cells are common in patients undergoing valve surgery for infective endocarditis, and ...
In an international, multicenter, randomized, double-blind trial, we assigned critically ill adults to receive either the freshest available, compatible, allogeneic red cells (short-term storage group ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback